A PHASE III, RANDOMISED, OPEN-LABEL, SPONSOR-BLINDED, MULTICENTRE STUDY OF RILVEGOSTOMIG IN COMBINATION WITH BEVACIZUMAB WITH OR WITHOUT TREMELIMUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (ARTEMIDE-HCC01)

Registry ID

D7029C00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2025-06-02

Last update

2025-02-28

Conditions

• ADVANCED HEPATOCELLULAR CARCINOMA

Related clinical trials

• A RANDOMIZED PHASE 2 STUDY OF CASDOZOKITUG IN COMBINATION WITH TORIPALIMAB PLUS BEVACIZUMAB IN PARTICIPANTS WITH UNRESECTABLE AND/OR LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
• A MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF TYRA-430 IN ADVANCED HEPATOCELLULAR CARCINOMA AND OTHER SOLID TUMORS WITH ACTIVATING FGF/FGFR PATHWAY ABERRATIONS (SURF431)
• A PHASE 1/2, SAFETY CONFIRMATION AND DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF RELATLIMAB IN COMBINATION WITH NIVOLUMAB AND BEVACIZUMAB IN TREATMENT-NAIVE ADVANCED/METASTATIC HEPATOCELLULAR CARCINOMA (RELATIVITY-106)
• A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF CABOZANTINIB (XL184) IN COMBINATION WITH ATEZOLIZUMAB VERSUS SORAFENIB IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO HAVE NOT RECEIVED PREVIOUS SYSTEMIC ANTICANCER THERAPY
• PEMBROLIZUMAB AND STEREOTACTIC RADIOTHERAPY COMBINED IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA - A PHASE II STUDY (PEMRAD)
• A PHASE III STUDY OF PEMBROLIZUMAB (MK-3475) VS. BEST SUPPORTIVE CARE AS SECOND-LINE THERAPY IN SUBJECTS WITH PREVIOUSLY SYSTEMICALLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (KEYNOTE-240)

View on source registry